Document is current
Any future updates will be listed below
-
Authors
O’Malley, David
Lee, Sylvia
Psyrri, Amanda
Sukari, Ammar
Thomas, Sajeve
Wenham, Robert
Gogas, Helen
Jazaeri, Amir
Monk, Bradley
Rose, Peter
Reuda, Antonio
Finckenstein, Friedrich Graf
Jagasia, Madan
Fiaz, Rana
Garelik, Brigid
Shi, Wen
Desai, Anjali
Sulur, Giri
Chen, Guang
Wu, Xiao
Jimeno, Antonio
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03645928 at ClinicalTrials.govnct03108495 at ClinicalTrials.govDocuments that mention this clinical trial
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
https://doi.org/10.1136/jitc-2021-003499
458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC)
https://doi.org/10.1136/jitc-2021-sitc2021.458
492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers
https://doi.org/10.1136/jitc-2021-sitc2021.492
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
https://doi.org/10.1136/jitc-2021-002723
1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results
https://doi.org/10.1136/jitc-2024-sitc2024.1488
The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee
https://doi.org/10.1136/jitc-2025-013420
Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.
https://doi.org/10.1200/jco.2024.42.16_suppl.9505
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
https://doi.org/10.1136/jitc-2023-007218
Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
https://doi.org/10.1136/jitc-2020-000668
nct03108495 at ClinicalTrials.govDocuments that mention this clinical trial
Advances in immunotherapy in cervical cancer
https://doi.org/10.1136/ijgc-2022-003758
492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers
https://doi.org/10.1136/jitc-2021-sitc2021.492
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Documents that mention this clinical trial
Advances in immunotherapy in cervical cancer
https://doi.org/10.1136/ijgc-2022-003758
492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor-naïve patients with advanced cancers
https://doi.org/10.1136/jitc-2021-sitc2021.492
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
